antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2024-69-1-2-29-36ENXOEQantibiotics-1106Research ArticleЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯEXPERIMENTAL STUDIESМолекулярная характеристика ткани немелкоклеточного рака лёгкого по количественным показателям экспрессии прогестероновых рецепторовMolecular characteristics of non-small cell lung cancer tissue based on quantitative indicators of progesterone receptors expressionhttps://orcid.org/0000-0002-9931-1153РомановИ. П.RomanovI. P.

Романов Илья Павлович — аспирант, лаборант-исследователь

Каширское шоссе, д. 24, ФГБУ «НМИЦ онкологии им. Н. Н. Блохина», г. Москва, 1154768

ResearcherID: HLH-5540-2023

Ilia P. Romanov — graduate student, laboratory assistant-researcher of the Molecular Prognosis of Tumors group at the Laboratory of Molecular Genetic Diagnostics and Personalized Medicine, Scientific Research Institute for Experimental Diagnostics and Therapy of Tumors Department 

24 Kashirskoe highway, д. 24, N. N. Blokhin Russian Cancer Research Centre, Moscow, 1154768

ResearcherID: HLH-5540-2023

biosophy@yandex.ruhttps://orcid.org/0000-0002-7673-4284БогушТ. А.BogushT. A.

Богуш Татьяна Анатольевна — д. б. н., профессор, руководитель группы молекулярного прогноза опухолей лаборатории молекулярно-генетической диагностики и персонализированной медицины НИИ ЭДиТО

Москва

ResearcherID:  A-6522-2013. Scopus Author ID: 7006161773 

Tatiana A. Bogush — D. Sc. in Biology, Professor, Head of the Molecular Prognosis of Tumors group, Laboratory of Molecular Genetic Diagnostics and Personalized Medicine, Scientific Research Institute for Experimental Diagnostics and Therapy of Tumors Department 

Moscow

ResearcherID: A-6522-2013. Scopus Author ID: 7006161773 

https://orcid.org/0000-0002-2974-9555ЩербаковА. М.ScherbakovA. M.

Щербаков Александр Михайлович — к. б. н., старший научный сотрудник, исполняющий обязанности заведующего лаборатории онкопротеомики отдела экспериментальной биологии опухолей

Москва

ResearcherID: F-4914-2013. Scopus Author ID: 7003636718 

Alexander M. Scherbakov — Ph. D. in Biology, Senior Researcher, Acting Head of the Oncoproteomics Laboratory of the Experimental Tumor Biology Department

Moscow

ResearcherID: F-4914-2013. Scopus Author ID: 7003636718 

   

https://orcid.org/0000-0002-8495-7728АлимовА. А.AlimovA. A.

Алимов Андрей Анатольевич — к. б. н., doctor of philosophy, doctor of medicine, заведующий лабораторией молекулярной генетики сложно наследуемых заболеваний

Москва

ResearcherID: J-7358-2018. Scopus Author ID: 7007117627 

   

Andrei A. Alimov — Ph. D. in Biology, Doctor of philosophy, Doctor of medicine, Head of the Laboratory of Molecular Genetics of Complex Hereditary Diseases

Moscow

ResearcherID: J-7358-2018. Scopus Author ID: 7007117627

   

https://orcid.org/0000-0001-5601-3669БогушЕ. А.BogushE. A.

Богуш Елена Александровна — к. м. н., ассистент кафедры онкологии Института клинической медицины им. Н. В. Склифосовского

Москва

ResearcherID: S-1415-2019. Scopus Author ID: 6602587330 

Elena A. Bogush — Ph. D. in Medicine, Assistant of the Department of Oncology, N. V. Sklifosovskiy Institute of Clinical Medicine

Moscow

ResearcherID: S-1415-2019. Scopus Author ID: 6602587330 

   

https://orcid.org/0000-0001-5969-0219РавчееваА. Б.RavcheevaA.  B.

Равчеева Анна Борисовна — к. б. н., младший научный сотрудник группы молекулярного прогноза опухолей лаборатории молекулярно-генетической диагностики и персонализированной медицины НИИ ЭДиТО

Москва

ResearcherID: R-9724-2019. Scopus Author ID: 7801332514 

Anna B. Ravcheeva — Ph. D. in Biology, Junior Researcher of the Molecular Prognosis of Tumors group, Laboratory of Molecular Genetic Diagnostics and Personalized Medicine, Scientific Research Institute for Experimental Diagnostics and Therapy of Tumors Department

Moscow

ResearcherID: R-9724-2019. Scopus Author ID: 7801332514

https://orcid.org/0000-0002-9931-1153ЛиА.LeeA.

Ли Алексей — лаборант-исследователь группы молекулярного прогноза опухолей лаборатории молекулярногенетической диагностики и персонализированной медицины НИИ ЭДиТО

Москва

ResearcherID: JWO-4459-2024

Lee Alexey — Laboratory assistant-researcher of the Molecular Prognosis of Tumors group at the Laboratory of Molecular Genetic Diagnostics and Personalized Medicine, Scientific Research Institute for Experimental Diagnostics and Therapy of Tumors Department

Moscow

ResearcherID: JWO-4459-2024 

https://orcid.org/0000-0002-8462-2178КосоруковВ. С.KosorukovV. S.

Косоруков Вячеслав Станиславович — к. б. н., заведующий лабораторией молекулярно-генетической диагностики и персонализированной медицины

Москва

ResearcherID: A-3901-2014. Scopus Author ID: 6505962801

Vyacheslav S. Kosorukov – Ph. D. in Biology, Head of the Laboratory of Molecular Genetic Diagnostics and Personalized Medicine

Moscow

ResearcherID: A-3901-2014. Scopus Author ID: 6505962801

   

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииРоссияN. N. Blokhin Russian Cancer Research Centre of the Ministry of Health of the Russian FederationRussian FederationФГБНУ «Медико-генетический научный центр им. акад. Н. П. Бочкова»РоссияResearch Centre for Medical Genetics named after Academician N. P. BochkovRussian FederationПервый Московский государственный медицинский университет им. И. М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation202416042024691-22936Copyright © Романов И.П., Богуш Т.А., Щербаков А.М., Алимов А.А., Богуш Е.А., Равчеева А.Б., Ли А., Косоруков В.С., 20242024Романов И.П., Богуш Т.А., Щербаков А.М., Алимов А.А., Богуш Е.А., Равчеева А.Б., Ли А., Косоруков В.С.Romanov I.P., Bogush T.A., Scherbakov A.M., Alimov A.A., Bogush E.A., Ravcheeva A.B., Lee A., Kosorukov V.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/1106Актуальность

Актуальность. Прогестероновые рецепторы (ПР) являются регуляторами клеточной пролиферации и потому могут рассматриваться как мишень таргетных препаратов в терапии онкологических заболеваний. При этом количественная оценка экспрессии ПР в ткани немелкоклеточного рака лёгкого (НМРЛ), которая до сих пор не была проведена в других работах, позволит определить перспективность применения модуляторов ПР для лечения данного заболевания и выявить потенциальную категорию наиболее восприимчивых к данным препаратам пациентов.

Цель исследования

Цель исследования. Охарактеризовать ткань НМРЛ по количественным показателям экспрессии ПР и определить корреляцию клинически значимых характеристик пациентов и клинико-морфологических параметров опухоли НМРЛ с уровнем экспрессии ПР для оценки перспективности применения модуляторов ПР в терапии данного заболевания.

Методы

Методы. Проведена оценка экспрессии ПР в 130 хирургических образцах НМРЛ иммунофлуоресцентным методом, ассоциированным с проточной цитометрией. Использованы первичные антитела к ПР (NBP2-46388) и вторичные — конъюгированные с DyLight650 (ab98729).

Результаты

Результаты. Экспрессия прогестероновых рецепторов выявлена во всех исследованных опухолях, при этом отмечено ненормальное распределение уровня экспрессии маркера (p=0,01). Средний уровень экспрессии составил 55,3±16,2%, а медиана — 57% с размахом 70%, что свидетельствует о гетерогенности экспрессии прогестероновых рецепторов в опухолях разных больных. Статистически значимых различий в уровне экспрессии прогестероновых рецепторов в зависимости от гистотипа и стадии немелкоклеточного рака лёгкого, а также от пола пациентов не обнаружено. Вместе с этим уровень экспрессии и частота встречаемости гиперэкспрессии прогестероновых рецепторов (>67%) в опухолях у некурящих пациентов выше, чем у курильщиков (р⩽0,02).

Заключение

Заключение. Высокая частота встречаемости и уровень экспрессии прогестероновых рецепторов в ткани немелкоклеточного рака лёгкого указывают на возможную эффективность применения их модуляторов при лечении этого заболевания, особенно у некурящих больных.

Background

Background. Progesterone receptors (PR) are regulators of cell proliferation and therefore can be considered as an aim for targeted medications in the treatment of oncological diseases. At the same time, a quantitative assessment of PR expression in the tissue of non-small cell lung cancer (NSCLC), which has not yet been carried out in other studies, will determine the possibility of using PR modulators for the treatment of this disease and identify the potential category of patients most susceptible to these drugs.

Purpose

Purpose. To characterize NSCLC by quantitative indicators of PR expression and to determine the correlation of clinically significant characteristics of patients and clinical and morphological parameters of a NSCLC tumor with the PR expression to assess the possibility of using PR modulators in the treatment of this disease.

Methods

Methods. The PR expression in 130 surgical samples of NSCLC was quantified using an immunofluorescence method associated with flow cytometry. Primary antibodies to PR (NBP2-46388) and secondary antibodies conjugated with DyLight650 (ab98729) were used.

Results

Results. The expression of progesterone receptors was detected in all the studied tumors; an abnormal distribution of the marker expression level was noted (P=0.01). The mean expression level was 55.3±16.2%, and the median was 57% with a range of 70%, which indicates heterogeneity of PR expression in tumors of different patients. There were no statistically significant differences in the level of PR expression depending on the histotype and stage of NSCLC, as well as on the sex of patients. At the same time, the level of expression and the frequency of overexpression of PR (>67%) in tumors in non-smoking patients are higher than in smokers (P⩽0.02).

Conclusion

Conclusion. The high frequency of occurrence and level of PR expression in NSCLC indicate the possible effectiveness of the use of their modulators in the treatment of this disease, especially in non-smoking patients.

прогестероновые рецепторынемелкоклеточный рак лёгкогопроточная цитометриямодуляторы стероидных рецепторовprogesterone receptorsnon-small cell lung cancerflow cytometrysteroid receptor modulatorsРабота выполнена при поддержке Министерства науки и высшего образования Российской Федерации (соглашение о субсидии № 075-15-20211060 от 28.09.2021) и в рамках научно-исследовательской работы ФГБУ «Национальный медицинский центр онкологии им. Н. Н. Блохина» Минздрава России 2023–2025 гг. (регистрационный № 123021500076-3).ReferencesHerbst R.S., Morgensztern D., Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018; 553 (7689): 446–454. doi: 10.1038/nature25183.Herbst R.S., Morgensztern D., Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018; 553 (7689): 446–454. doi: 10.1038/nature25183.Ahmad N., Kumar R. Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett. 2011; 300 (1): 1–9. doi: 10.1016/j.canlet.2010.09.008.Ahmad N., Kumar R. Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett. 2011; 300 (1): 1–9. doi: 10.1016/j.canlet.2010.09.008.Siegfried J.M., Stabile L.P. Estrongenic steroid hormones in lung cancer. Semin Oncol. 2014; 41 (1): 5–16. doi: 10.1053/j.seminoncol.2013.12.009.Siegfried J.M., Stabile L.P. Estrongenic steroid hormones in lung cancer. Semin Oncol. 2014; 41 (1): 5–16. doi: 10.1053/j.seminoncol.2013.12.009.Ishibashi H., Suzuki T., Suzuki S., et al. Progesterone receptor in nonsmall cell lung cancer — a potent prognostic factor and possible target for endocrine therapy. Cancer Res. 2005; 65 (14): 6450–6458. doi: 10.1158/0008-5472. CAN-04-3087.Ishibashi H., Suzuki T., Suzuki S., et al. Progesterone receptor in nonsmall cell lung cancer — a potent prognostic factor and possible target for endocrine therapy. Cancer Res. 2005; 65 (14): 6450–6458. doi: 10.1158/0008-5472. CAN-04-3087.Nishizawa Y., Yamasaki M., Katayama H., Amakata Y., Fushiki S., Nishizawa Y. Establishment of a progesterone-sensitive cell line from human lung cancer. Oncol Rep. 2007; 18 (3): 685–690.Nishizawa Y., Yamasaki M., Katayama H., Amakata Y., Fushiki S., Nishizawa Y. Establishment of a progesterone-sensitive cell line from human lung cancer. Oncol Rep. 2007; 18 (3): 685–690.Marquez-Garban D.C., Mah V., Alavi M. et al. Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids. 2011; 76 (9): 910–920. doi: 10.1016/j.steroids.2011.04.015.Marquez-Garban D.C., Mah V., Alavi M. et al. Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids. 2011; 76 (9): 910–920. doi: 10.1016/j.steroids.2011.04.015.Kapperman H.E., Goyeneche A.A., Telleria C.M. Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin. Cancer Cell Int. 2018; 18: 185. Published 2018 Nov 15. doi: 10.1186/s12935-018-0683-z.Kapperman H.E., Goyeneche A.A., Telleria C.M. Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin. Cancer Cell Int. 2018; 18: 185. Published 2018 Nov 15. doi: 10.1186/s12935-018-0683-z.Zheng G., Shen Z., Chen H. et al. Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway. Biomed Pharmacother. 2017; 90: 437–445. doi: 10.1016/j.biopha.2017.03.091.Zheng G., Shen Z., Chen H. et al. Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway. Biomed Pharmacother. 2017; 90: 437–445. doi: 10.1016/j.biopha.2017.03.091.Check J.H., Sansoucie L., Chern J., Dix E. Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res. 2010; 30 (1): 119–122.Check J.H., Sansoucie L., Chern J., Dix E. Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res. 2010; 30 (1): 119–122.Skov B.G., Fischer B.M., Pappot H. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer. 2008; 59 (1): 88–94. doi: 10.1016/j.lungcan. 2007.07.025.Skov B.G., Fischer B.M., Pappot H. Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer. 2008; 59 (1): 88–94. doi: 10.1016/j.lungcan. 2007.07.025.Di Nunno L., Larsson L.G., Rinehart J.J., Beissner R.S. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med. 2000; 124 (10): 1467–1470. doi: 10.5858/2000-124-1467-EAPRIN.Di Nunno L., Larsson L.G., Rinehart J.J., Beissner R.S. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med. 2000; 124 (10): 1467–1470. doi: 10.5858/2000-124-1467-EAPRIN.Radzikowska E., Langfort R., Giedronowicz D. Estrogen and progesterone receptors in non small cell lung cancer patients. Ann Thorac Cardiovasc Surg. 2002; 8 (2): 69–73.Radzikowska E., Langfort R., Giedronowicz D. Estrogen and progesterone receptors in non small cell lung cancer patients. Ann Thorac Cardiovasc Surg. 2002; 8 (2): 69–73.Abe K., Miki Y., Ono K. et al. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol. 2010; 41 (2): 190–198. doi: 10.1016/j.humpath.2009.07.010.Abe K., Miki Y., Ono K. et al. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol. 2010; 41 (2): 190–198. doi: 10.1016/j.humpath.2009.07.010.Naoki Y., Kawaguchi T., Isa SI. et al. Molecular epidemiological study on passive smoking and estrogen receptor expression in neversmokers with non-small cell lung cancer. Osaka City Med J. 2016; 62 (2): 77–84.Naoki Y., Kawaguchi T., Isa SI. et al. Molecular epidemiological study on passive smoking and estrogen receptor expression in neversmokers with non-small cell lung cancer. Osaka City Med J. 2016; 62 (2): 77–84.Stabile L.P., Dacic S., Land S.R. et al. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res. 2011; 17 (1): 154–164. doi: 10.1158/1078-0432.CCR-10-0992.Stabile L.P., Dacic S., Land S.R. et al. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res. 2011; 17 (1): 154–164. doi: 10.1158/1078-0432.CCR-10-0992.Berardi R., Morgese F., Santinelli A. et al. Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. Oncotarget. 2016; 7 (50): 82648–82657. doi: 10.18632/oncotarget.12244.Berardi R., Morgese F., Santinelli A. et al. Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. Oncotarget. 2016; 7 (50): 82648–82657. doi: 10.18632/oncotarget.12244.Asavasupreechar T., Saito R., Miki Y., Edwards D.P., Boonyaratanakornkit V., Sasano H. SUN-742 Roles of Progesterone Receptor Isoform B in NonSmall Cell Lung Cancer Tumor Progression. J Endocr Soc. 2020; 4 (Suppl 1): SUN-742. doi: 10.1210/jendso/bvaa046.1568.Asavasupreechar T., Saito R., Miki Y., Edwards D.P., Boonyaratanakornkit V., Sasano H. SUN-742 Roles of Progesterone Receptor Isoform B in NonSmall Cell Lung Cancer Tumor Progression. J Endocr Soc. 2020; 4 (Suppl 1): SUN-742. doi: 10.1210/jendso/bvaa046.1568.Jeong Y., Xie Y., Xiao G. et al. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med. 2010; 7 (12): e1000378. doi: 10.1371/journal.pmed.1000378.Jeong Y., Xie Y., Xiao G. et al. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med. 2010; 7 (12): e1000378. doi: 10.1371/journal.pmed.1000378.Li Y., Huang C., Kavlashvili T. et al. Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors. Am J Cancer Res. 2020; 10 (6): 1827–1843.Li Y., Huang C., Kavlashvili T. et al. Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors. Am J Cancer Res. 2020; 10 (6): 1827–1843.Skjefstad K., Richardsen E., Donnem T. et al. The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: Gender-related impacts and correlation with disease-specific survival. Steroids. 2015; 98: 29–36. doi: 10.1016/j.steroids.2015.01.020.Skjefstad K., Richardsen E., Donnem T. et al. The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: Gender-related impacts and correlation with disease-specific survival. Steroids. 2015; 98: 29–36. doi: 10.1016/j.steroids.2015.01.020.Rades D., Setter C., Dahl O., Schild SE., Noack F. The prognostic impact of tumor cell expression of estrogen receptor-α, progesterone receptor., and androgen receptor in patients irradiated for nonsmall cell lung cancer. Cancer. 2012; 118 (1): 157–163. doi: 10.1002/cncr.26282.Rades D., Setter C., Dahl O., Schild SE., Noack F. The prognostic impact of tumor cell expression of estrogen receptor-α, progesterone receptor., and androgen receptor in patients irradiated for nonsmall cell lung cancer. Cancer. 2012; 118 (1): 157–163. doi: 10.1002/cncr.26282.Raso M.G., Behrens C., Herynk M.H. et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009; 15 (17): 5359–5368. doi: 10.1158/1078-0432.CCR-09-0033.Raso M.G., Behrens C., Herynk M.H. et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009; 15 (17): 5359–5368. doi: 10.1158/1078-0432.CCR-09-0033.Lee J.H., Kim H.K., Shin B.K. Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma. J Pathol Transl Med. 2020; 54 (1): 103–111. doi: 10.4132/jptm.2019.10.12.Lee J.H., Kim H.K., Shin B.K. Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma. J Pathol Transl Med. 2020; 54 (1): 103–111. doi: 10.4132/jptm.2019.10.12.Check J.H., Poretta T., Check D., Srivastava M. Lung Cancer — Standard Therapy and the Use of a Novel., Highly Effective., Well Tolerated., Treatment With Progesterone Receptor Modulators. Anticancer Res. 2023; 43 (3): 951–965. doi: 10.21873/anticanres.16240.Check J.H., Poretta T., Check D., Srivastava M. Lung Cancer — Standard Therapy and the Use of a Novel., Highly Effective., Well Tolerated., Treatment With Progesterone Receptor Modulators. Anticancer Res. 2023; 43 (3): 951–965. doi: 10.21873/anticanres.16240.Bogush T.A., Basharina A.A., Eliseeva B.K. et al. A new approach to epithelial-mesenchymal transition diagnostics in epithelial tumors: double immunofluorescent staining and flow cytometry. Biotechniques. 2020; 69 (4): 257–263. doi: 10.2144/btn-2020-0024.Bogush T.A., Basharina A.A., Eliseeva B.K. et al. A new approach to epithelial-mesenchymal transition diagnostics in epithelial tumors: double immunofluorescent staining and flow cytometry. Biotechniques. 2020; 69 (4): 257–263. doi: 10.2144/btn-2020-0024.Bouchard-Fortier A., Provencher L., Blanchette C., Diorio C. Prognostic and predictive value of low estrogen receptor expression in breast cancer. Curr Oncol. 2017; 24 (2): e106–e114. doi: 10.3747/co.24.3238.Bouchard-Fortier A., Provencher L., Blanchette C., Diorio C. Prognostic and predictive value of low estrogen receptor expression in breast cancer. Curr Oncol. 2017; 24 (2): e106–e114. doi: 10.3747/co.24.3238.

The authors declare that there are no conflicts of interest present.